This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Pediatrix Medical Group (MD) and Travere Therapeutics (TVTX)

Tipranks - Tue Jul 14, 8:54AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pediatrix Medical Group (MD) and Travere Therapeutics (TVTX).

TipRanks Welcomes a New ETF – NYSE:RANK

Pediatrix Medical Group (MD)

Mizuho Securities analyst Ann Hynes maintained a Hold rating on Pediatrix Medical Group today and set a price target of $27.00. The company’s shares closed last Monday at $26.38.

According to TipRanks.com, Hynes is a 5-star analyst with an average return of 8.6% and a 59.1% success rate. Hynes covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Fortrea Holdings Inc., and Charles River Labs. ;'>

Pediatrix Medical Group has an analyst consensus of Moderate Buy, with a price target consensus of $24.80, which is a -5.6% downside from current levels. In a report issued on July 4, TipRanks – Anthropic also reiterated a Hold rating on the stock with a $29.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Travere Therapeutics (TVTX)

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Travere Therapeutics, with a price target of $61.00. The company’s shares closed last Monday at $54.64.

According to TipRanks.com, Chico is a 5-star analyst with an average return of 15.4% and a 54.8% success rate. Chico covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ultragenyx Pharmaceutical, and Maze Therapeutics, Inc. ;'>

Currently, the analyst consensus on Travere Therapeutics is a Strong Buy with an average price target of $58.33, which is a 3.1% upside from current levels. In a report issued on July 7, Canaccord Genuity also maintained a Buy rating on the stock with a $56.00 price target.

Read More on MD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.